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Acquired neuromyotonia encompasses a group of inﬂammatory disorders characterized by symptoms reﬂecting peripheral nerve
hyperexcitability, which may be clinically confused in the early stages with amyotrophic lateral sclerosis. Despite a clear
peripheral nerve focus, it remains unclear whether the ectopic activity in acquired neuromyotonia receives a central contribution.
To clarify whether cortical hyperexcitability contributes to development of clinical features of acquired neuromyotonia, the
present study investigated whether threshold tracking transcranial magnetic stimulation could detect cortical hyperexcitability
in acquired neuromyotonia, and whether this technique could differentiate acquired neuromyotonia from amyotrophic lateral
sclerosis. Cortical excitability studies were undertaken in 18 patients with acquired neuromyotonia and 104 patients
with amyotrophic lateral sclerosis, with results compared to 62 normal controls. Short-interval intracortical inhibition in
patients with acquired neuromyotonia was signiﬁcantly different when compared to patients with amyotrophic lateral sclerosis
(averaged short interval intracortical inhibition acquired neuromyotonia 11.3 1.9%; amyotrophic lateral sclerosis 2.6 0.9%,
P50.001). In addition, the motor evoked potential amplitudes (acquired neuromyotonia 21.0 3.1%; amyotrophic lateral scler-
osis 38.1 2.2%, P50.0001), intracortical facilitation (acquired neuromyotonia  0.9 1.3%; amyotrophic lateral sclerosis
 2.3 0.6%, P50.0001), resting motor thresholds (acquired neuromyotonia 62.2 1.6%; amyotrophic lateral scler-
osis 57.2 0.9%, P50.05) and cortical silent period durations (acquired neuromyotonia 212.8 6.9ms; amyotrophic lateral
sclerosis 181.1 4.3ms, P50.0001) were signiﬁcantly different between patients with acquired neuromyotonia and amyotroph-
ic lateral sclerosis. Threshold tracking transcranial magnetic stimulation established corticomotoneuronal integrity in acquired
neuromyotonia, arguing against a contribution of central processes to the development of nerve hyperexcitability in acquired
neuromyotonia.
Keywords: acquired neuromyotonia; amyotrophic lateral sclerosis; cortical excitability
Abbreviations: ALS = amyotrophic lateral sclerosis; CMAP = compound muscle action potential; MEP = motor evoked potential;
SICI = short interval intracortical inhibition; SR = stimulus response; TMS = transcranial magnetic stimulation; VGKC = voltage-gated
K
+ channels
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Acquired neuromyotonia refers to a group of disorders character-
ized by continuous ectopic nerve activity, manifesting clinically
with cramps, fasciculations and stiffness (Hart et al., 2002).
These symptoms may be accompanied by hyperhidrosis, sensory
abnormalities and central nervous system (CNS) features, referred
to as Morvan’s syndrome (Hart et al., 2002). In  40% of cases,
antibodies against voltage-gated K
+ channels (VGKC) are present
and may bind to both central and peripheral neurons (Hart et al.,
1997, 2002; Kleopa et al., 2006).
Acquired neuromyotonia is characterized by the presence of
spontaneous activity including positive sharp-waves and ﬁbrillation
potentials, fasciculations, myokymia, multiple discharges, muscle
cramps and repetitive after-discharges in response to a voluntary
contraction (Warmolts and Mendell, 1980; Hart et al., 1997;
Kiernan et al., 2001). There have been varied ﬁndings regarding
the origin of this ectopic activity in acquired neuromyotonia. Most
studies have suggested that the ectopic focus arises at the unmye-
linated distal nerve terminal (Isaacs, 1961; Wallis and Plum, 1969;
Lutschg et al., 1978; Lance et al., 1979; Warmolts and Mendell,
1980; Auger, 1994; Deymeer et al., 1998; Maddison et al., 1999;
Kiernan et al., 2001; Hart et al., 2002; Oh et al., 2003). Antidromic
propagation and axonal reﬂexes may also contribute to the gener-
ation of ectopic activity (Auger, 1994). Alternatively, it has been
proposed that the ectopic focus may arise at either the anterior
horn cell level, or even more centrally (Irani et al., 1977;
Hosokawa et al., 1987; Hart et al., 1996), as supported by the
presence CNS symptoms and inﬂammatory changes, such as the
presence of oligoclonal bands on cerebrospinal ﬂuid analysis, in
patients with acquired neuromyotonia (Newsom-Davis and Mills,
1993; Newsom-Davis, 1997; Liguori et al., 2001; Hart et al., 2002).
Separately, acquired neuromyotonia may be clinically misdiag-
nosed as amyotrophic lateral sclerosis (ALS) (Rowland and
Shneider, 2001), particularly in the early stages of ALS where
widespread fasciculations may be evident in the absence of
other clinical features of ALS (Hirota et al., 2000; Shiga et al.,
2000; de Carvalho and Swash, 2004; Kleine et al., 2008). Of
relevance, cortical hyperexcitability has been associated with the
development of widespread fasciculations in ALS (Kaji et al., 1993;
de Carvalho et al., 2000; Hirota et al., 2000; Shiga et al., 2000;
Kleine et al., 2008), although there have been limited, if any,
studies that assessed the cortical function in acquired
neuromyotonia.
Cortical function may be clinically assessed using paired-pulse
transcranial magnetic stimulation (TMS) techniques (Vucic et al.,
2006), which had established that cortical hyperexcitability is an
early feature in sporadic ALS (Vucic and Kiernan, 2006b), and
precedes the clinical onset of familial ALS (Vucic et al., 2008).
Consequently, the present study used novel paired-pulse TMS
techniques (Vucic et al., 2006) to assess whether cortical hyper-
excitability was evident in acquired neuromyotonia, and whether
the presence of cortical hyperexcitability in ALS would enable one
to differentiate the two diseases early in the disease process,
before the development of the more characteristic neurophysio-
logical changes of ALS.
Materials and methods
Patients
Studies were undertaken in 18 patients with acquired neuromyotonia
(13 males, 5 females: age range 33–65 years, mean age: 50 years),
diagnosed according to previously established criteria with symptoms
or signs of muscle twitching or muscle cramps affecting at least two
regions of skeletal muscles (Hart et al., 2002). All patients demon-
strated the characteristic EMG discharges consisting of doublet, triplet
or multiplet single motor unit discharges with a high intraburst fre-
quency of between 40–400/s (Fig. 1) (Hart et al., 1997; Kiernan et al.,
2001). Patients were clinically assessed with muscle strength grades
using the Medical Research Council clinical grading of power (Medical
Research Council, 1976). Serum samples from all patients suspected
of a diagnosis of acquired neuromyotonia were tested using a
125I- -dendrotoxin radioimmunoprecipitation assay for anti-VGKC
antibodies, which has a sensitivity of approximately 50% (Hart
et al., 1997; Kiernan et al., 2001).
Studies were also undertaken on 104 patients with deﬁnite or prob-
able ALS (66 males, 38 females, aged 25–80 years, mean age:
58 years) as deﬁned according to the revised El Escorial criteria
(Brooks et al., 2000). The mean disease duration to the time of testing
was 18 1.8 months, with a mean ALS functional rating scale-revised
score of 39 0.9. There was moderate weakness of the target
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Figure 1 A raster display of doublet and triplet discharges along
with fasciculations in a representative patient with acquired
neuromyotonia (Patient 18, Table 1).
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Council score of 4. Limb-onset disease was reported by 77% of pa-
tients with ALS, while bulbar-onset disease was evident in 23% of
patients. Clinically, patients with ALS exhibited less fasciculations
when compared to the acquired neuromyotonia cohort, although a
formal fasciculation frequency was not calculated. Patients with ALS
and acquired neuromyotonia cohort were clinically quantiﬁed using the
same method. Using the compound muscle action potential (CMAP)
amplitude as a broad marker of disease severity, with CMAP amplitude
54mV a cut-off for more advanced disease (Vucic and Kiernan,
2006b), it was evident that the majority of patients with ALS (61%)
exhibited less severe disease at the time of testing. Results from
acquired neuromyotonia and patients with ALS were compared to
control data obtained from 62 normal controls (31 males; 31 females,
aged 23–83 years, mean: 46 years) (Vucic and Kiernan, 2006b). All
patients gave informed consent to the procedures, which were
approved by the South East Sydney Area Health Service Human
Research Ethics Committee.
Peripheral nerve studies
Prior to undertaking cortical excitability studies, conventional nerve
conduction studies were undertaken on all patients. The CMAP was
recorded from the abductor pollicis brevis muscle as were the distal
motor and F-wave latencies. From the CMAP amplitude, the neuro-
physiological index was calculated according to a previously estab-
lished formula (de Carvalho and Swash, 2000).
Cortical excitability
Cortical excitability was assessed by applying a 90mm circular coil to
the motor cortex oriented to induce current ﬂow in a posterior-anterior
direction. The coil was adjusted until the optimal position for a motor
evoked response was obtained from the abductor pollicis brevis
muscle. Currents were generated by two high-power magnetic stimu-
lators which were connected via a BiStim (Magstim Co., Whitland,
South West Wales, UK) such that conditioning and test stimuli could
be independently set and delivered through the one coil.
In the conventional paired-pulse technique, the conditioning and
test stimuli are kept at constant intensity, and changes in the motor
evoked potential (MEP) amplitude are measured. In the present study
the amplitude of the MEP response was ﬁxed and changes in the test
stimulus intensity required to generate this target response, when
preceded by either sub- or supra-threshold conditioning stimuli, were
measured as previously described (Vucic et al., 2006).
The threshold tracking strategy used a target response of 0.2mV as
previously reported (Fisher et al., 2002; Vucic et al., 2006). Resting
motor threshold was deﬁned as the stimulus intensity required to pro-
duce and maintain this target MEP response. Initially, the stimulus
response (SR) curve for cortical stimulation was determined by increas-
ing the intensity of the magnetic stimulus to the following levels: 60,
80, 90, 100, 110, 120, 130, 140 and 150% resting motor threshold.
Three stimuli were delivered at each level of stimulus intensity.
Although the SR curve was recorded in all patients, the maximum
MEP amplitude (mV) and MEP onset latency (ms), recorded at 150%
resting motor threshold, was used in group comparisons. Central motor
conduction time (cortical silent period, ms) was calculated according
to the F-wave method formula (Mills and Murray, 1986):
CMCT ¼ MEP latency  ½ DML þ Fmin 1 =2
where DML represents the distal motor latency and Fmin the minimum
F-wave latency.
Cortical silent period was induced by single-pulse TMS and recorded
while patients performed a weak voluntary contraction. The duration
of the silent period was measured from the beginning of MEP to the
return of EMG activity (Cantello et al., 1992).
Short interval intracortical inhibition (SICI) and intracortical
facilitation were measured according to previously devised threshold
tracking protocols (Vucic et al., 2006). SICI was determined by using
subthreshold conditioning stimuli (70% resting motor threshold) at
increasing interstimulus intervals delivered in a sequential order as fol-
lows: 1, 1.5, 2, 2.5, 3, 3.5, 4, 5 and 7ms. Intracortical facilitation was
determined over the following interstimulus intervals: 10, 15, 20
and 30ms, using a subthreshold conditioning stimulus intensity set
to 70% resting motor threshold. All neurophysiological parameters,
including SICI and intracortical facilitation, were recorded with the
target muscle at rest. The target muscle was closely observed for
the presence of voluntary activity as recorded by surface electrodes
and also viewed on a monitor, and the patients and subjects were
asked to relax the target muscle if the examiner noted the appearance
of any voluntary activity. SICI was measured as the increase in the test
stimulus intensity required to evoke the target MEP. SICI was calcu-
lated off-line as follows (Fisher et al., 2002; Vucic et al., 2006):
SICI ¼ [Conditioned test stimulus intensity   RMT =RMT   100
Facilitation was measured as the decrease in the conditioned test
stimulus intensity required to evoke a target MEP.
Recordings of CMAP and MEP were ampliﬁed and ﬁltered
(3Hz–3kHz)using a GRASS ICP511 AC ampliﬁer (Grass-Telefactor,
Astro-Med Inc., West Warwick, RI, USA) and sampled at 10kHz
using a 12-bit data acquisition card (National Instruments
PCI-MIO-16E-4). Data acquisition and stimulation delivery were con-
trolled by QTRACS software (Institute of Neurology, Queen Square,
London, UK).
Statistical analysis
Student’s t-test and one-way analysis of variance were used to
compare mean differences. A probability (P) value of50.05 was
considered statistically signiﬁcant. Results are expressed as
mean standard error of the mean.
Results
The clinical features of the 18 patients with acquired neuromyo-
tonia are summarized in Table 1. All patients exhibited typical
clinical features of acquired neuromyotonia including generalized
cramps, fasciculations and stiffness. On EMG testing, doublet,
triplet, multiple motor unit discharges and fasciculations were
reported in all patients, in keeping with previous reports
(Newsom-Davis and Mills, 1993; Kiernan et al., 2001; Hart
et al., 2002). Anti-VGKC antibodies were present in 33% of
patients with acquired neuromyotonia. One patient exhibited a
sensorimotor peripheral neuropathy with associated weakness of
distal muscle groups in the upper and lower limbs, including weak-
ness of thumb and ﬁnger abduction, ankle dorsiﬂexion and ﬂexion
and extension of the toes, all exhibiting an MRC grade 4.
Of relevance to the clinical overlap between acquired neuro-
myotonia and ALS, particularly in the early disease stages, 40%
of patients with acquired neuromyotonia from the present series
were initially erroneously diagnosed with ALS. Over the time of
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all patients based on further clinical assessment, neurophysiological
investigation and lack of clinical progression.
Peripheral nerve studies
The CMAP amplitude (acquired neuromyotonia 8.3 1.1mV; con-
trols 10.4 0.7mV) and neurophysiological index (acquired neu-
romyotonia 1.8 0.3; controls 2.5 0.2) were similar in patients
with acquired neuromyotonia and controls. However, there was a
signiﬁcant difference in the CMAP amplitude (5.6 0.3mV,
P50.01) and neurophysiological index (0.7 0.1, P50.01) be-
tween acquired neuromyotonia and patients with ALS, being
reduced in the latter group.
Cortical excitability
The motor cortex was excitable in all patients with acquired
neuromyotonia. Central motor conduction time was comparable
across all groups (acquired neuromyotonia 5.3 0.3ms; ALS
5.3 0.2ms; controls 5.3 0.2ms). The resting motor threshold,
deﬁned as the unconditioned stimulus intensity required to
produce and maintain the target MEP response, was signiﬁcantly
greater in acquired neuromyotonia (acquired neuromyotonia
62.2 1.6%; controls 60.0 1.0%), when compared to ALS
(ALS 57.2 0.9%, F=3.4, P50.05). Furthermore, the MEP
amplitude, expressed as a percentage of the CMAP amplitude
recorded following electrical stimulation, was signiﬁcantly different
between acquired neuromyotonia (21.0 3.1%; controls
24.7 1.8%) and patients with ALS (38.1 2.2%, F=77.8,
P50.0001).
There was no signiﬁcant difference in the cortical silent period
(F=1.592, P=0.211), MEP amplitude (F=1.184, P=0.312)
and resting motor threshold (F=1.483, P=0.235) in acquired
neuromyotonia patients with CNS features compared to acquired
neuromyotonia patients without CNS features and controls. In
addition, there was no signiﬁcant difference in the cortical silent
period (F=1.450, P=0.241), MEP amplitude (F=2.195, P=0.119)
and resting motor threshold (F=2.224, P=0.116) in patients
with acquired neuromyotonia that tested positive for
anti-VGKC antibodies compared to those patients with acquired
neuromyotonia that tested negative for anti-VGKC antibodies and
controls.
SICI
SICI has been deﬁned as an increase in the test stimulus intensity
required to track a constant target MEP of 0.2mV. In normal
controls, two peaks of SICI were evident, a smaller peak at
interstimulus interval of 1ms and a larger peak at 3ms.
SICI was signiﬁcantly different between acquired neuromyotonia
and ALS, reduced in the latter, and consistent with cortical hyper-
excitability (Fig. 2). In addition, peak SICI at an interstimulus
interval of 1ms (acquired neuromyotonia 8.3 1.5%; controls
7.5 0.8%; ALS, 1.7 0.7%, F=16.1, P50.001; Fig. 3A)
and at interstimulus interval 3ms (acquired neuromyotonia
17.1 2.8%; controls 16.1 1.2%; ALS 5.4 1.2%, F=15.4
P50.001; Fig. 3B) were signiﬁcantly different. In further compari-
sons to acquired neuromyotonia, limb-onset ALS patients, who
clinically exhibited more frequent fasciculations than bulbar-onset
ALS patients, disclosed signiﬁcantly reduced SICI (4.3 1.4%,
P50.01).
Table 1 Clinical details for the 18 patients with acquired neuromyotonia
Patients Age (years)
sex
Fasciculations/
neuromyotonia
CNS features
(mood disturbance,
insomnia and confusion)
Anti-VGKC
antibodies
Autoimmune
accompaniments
1 40M Present Yes Negative Yes
2 74M Present Yes Negative Yes
3 71M Present No Negative No
4 58M Present Yes Negative Yes
5 17M Present Yes Positive No
6 35M Present Yes Negative Yes
7 43F Present No Negative No
8 59M Present Yes Negative Yes
9 58M Present No Negative Yes
10 61F Present No Negative No
11 38M Present Yes Negative Yes
12 52M Present No Negative No
13 51F Present No Negative No
14 23M Present No Positive Yes
15 47F Present Yes Positive Yes
16 53F Present No Positive No
17 56M Present No Positive No
18 55M Present Yes Positive No
Mean (SEM) 50 (5.6)
Fasciculation potentials and neuromyotonia were evident in all patients with acquired neuromyotonia. Antibodies to VGKC were evident in 33% of patients. The phenotype
expression of CNS was evident in 50% of patients with acquired neuromyotonia. Other autoimmune accompaniments, including myasthenia gravis, diabetes mellitus and
rheumatoid arthritis were evident in 50% of patients.
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cantly different in patients with acquired neuromyotonia with or
without CNS symptoms, or when compared to controls (F=2.40,
P=0.10). In addition, there was no signiﬁcant difference of aver-
aged SICI in patients with acquired neuromyotonia that tested
positive for anti-VGKC antibodies, as compared to those that
tested negative for anti-VGKC antibodies and controls
(F=2.207, P=0.118).
Following SICI, a period of intracortical facilitation developed,
marked by a decrease in the test stimulus intensity required to
maintain the target MEP of 0.2mV (Vucic et al., 2006).
Although there was no signiﬁcant difference in peak intracortical
facilitation at interstimulus interval 15ms (P=0.37), there was a
signiﬁcant difference of averaged intracortical facilitation, from
interstimulus interval of 10–30ms, between acquired neuromyo-
tonia and patients with ALS, being increased in the latter (acquired
neuromyotonia  0.9 1.3%; controls  0.8 0.7%; ALS
 2.3 0.6%, F=64.8, P50.0001 Fig. 2).
Cortical silent period
In a contracting muscle, MEP is followed by a period of electrical
silence that interferes with ongoing EMG activity, known as the
cortical silent period. In the present series, the increase in the
cortical silent period recruitment curve was non-linear in patients
with acquired neuromyotonia, similar to the relationship estab-
lished previously for control subjects (Vucic et al., 2006). As stimu-
lus intensity increased from 60 to 150% resting motor threshold,
the mean cortical silent period duration increased from 0 to
212.8 6.9ms in patients with acquired neuromyotonia and
was signiﬁcantly different to patients with ALS, where it was
reduced (ALS 0–181.1 4.3ms; controls 208.2 3.1ms,
F=13.2, P50.0001).
Discussion
Using novel threshold tracking TMS techniques the present study
has established, for the ﬁrst time, functional integrity of cortico-
motoneurons in patients with acquired neuromyotonia, arguing
against a signiﬁcant central contribution to the process of nerve
hyperexcitability, and clearly differentiating acquired neuromyoto-
nia from ALS. In addition, there was no difference in cortical
excitability in acquired neuromyotonia patients with or without
CNS symptoms, or those testing positive or negative for
anti-VGKC antibodies. In contrast, the present study suggests
that cortical hyperexcitability is speciﬁc to ALS across the spectrum
of clinical presentations that report hyperexcitability and that,
since the threshold tracking TMS technique reliably differentiates
acquired neuromyotonia from ALS, it may be useful, particularly in
the early disease stages where diagnostic confusion is possible.
What underlies the generation of
ectopic activity in acquired
neuromyotonia?
The presence of ectopic motor activity is a clinical hallmark in both
acquired neuromyotonia and ALS (Rowland and Shneider, 2001;
Hart et al., 2002; de Carvalho et al., 2008). In ALS, up-regulation
of axonal persistent Na
+ conductances (Kanai et al., 2006; Vucic
and Kiernan, 2006a) and corticomotoneuronal mediated anterior
horn cell hyperexcitability (Hirota et al., 2000; Shiga et al., 2000;
Kleine et al., 2008), have been identiﬁed as mechanisms under-
lying the generation of this ectopic activity. In acquired neuromyo-
tonia, the mechanisms underlying the generation of this ectopic
Figure 3 Peak short interval intracortical inhibition (SICI) at
interstimulus interval of (A) 1ms and (B) 3ms was signiﬁcantly
different between acquired neuromyotonia (aNMT) and amyo-
trophic lateral sclerosis (ALS) patients, reduced in the latter and
consistent with cortical hyperexcitability. ***P50.001.
Figure 2 Short interval intracortical inhibition (SICI), deﬁned as
an increase in the test stimulus intensity required to track a
constant target MEP response of 0.2mV, was signiﬁcantly
different between acquired neuromyotonia (aNMT) and
amyotrophic lateral sclerosis (ALS) patients.
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up-regulation of persistent Na
+ conductances underlies the gener-
ation of ectopic activity in acquired neuromyotonia, as indicated by
an increase in the strength-duration time constant (Maddison et al.,
1999), this has not been a universal feature across acquired neuro-
myotonia cohorts (Kiernan et al., 2001). The discrepancies in these
peripheral ﬁndings strongly suggest that much of the ectopic activ-
ity in acquired neuromyotonia is generated at the motor nerve
terminal (Isaacs, 1961; Deymeer et al., 1998; Maddison et al.,
1999; Kiernan et al., 2001; Hart et al., 2002; Oh et al., 2003).
Alternatively, it has also been suggested that ectopic activity in
acquired neuromyotonia may arise at the level of the anterior horn
cell in association with CNS dysfunction secondary to binding of
anti-VGKC antibodies to central neurons (Irani et al., 1977;
Hosokawa et al., 1987; Hart et al., 1996; Newsom-Davis, 1997;
Kleopa et al., 2006). The ﬁnding of normal cortical excitability in
patients with acquired neuromyotonia from the present series
would argue against signiﬁcant CNS dysfunction, and supports
the notion that ectopic activity in acquired neuromyotonia pre-
dominantly arises peripherally. Speciﬁcally, blockade on the fast
paranodal K
+ channels on the peripheral axon by anti-VGKC anti-
bodies, may result in membrane depolarization, up-regulation of
persistent Na
+ conductances and thereby generation of ectopic
activity (Kiernan et al., 2001). Recent evidence indicates that
many of the high anti-VGKC antibodies are directed against
other proteins that are intimately associated with anti-VGKCs
such as Caspr2 at the juxtaparanodes, or Lgi1 in the molecular
layer of the hippocampus (Irani SR et al., submitted). The targets
for the antibodies in patients with aNMT, however, have not yet
been fully deﬁned.
It remains a possibility that excessive activity in corticomoto-
neurons, leading to activity-dependent hyperpolarization through
activation of the Na
+–K
+ pump (Vagg et al., 1998; Vucic and
Kiernan, 2007), could result in greater stimulus intensity or thresh-
olds being required to generate the target MEP response and
could have masked any underlying cortical hyperexcitability in
acquired neuromyotonia. However, this seems an unlikely explan-
ation for the ﬁndings since both SICI and intracortical facilitation
were measured by subtracting the conditioning-stimulus intensity
(Channel 3) from the unconditioned stimulus intensity (Channel 1,
see ‘Materials and methods’ section), thereby subtracting out any
‘noise’ activity, or excessive stimulus intensity from the ﬁnal
calculations.
In accordance to changes in SICI, the MEP amplitude was
increased in patients with ALS, most probably reﬂecting cortical
hyperexcitability and in keeping with previous reports (Eisen et al.,
1993; Zanette et al., 2002; Vucic and Kiernan, 2006b, 2008; Vucic
et al., 2008). Alternatively, it could be argued that the increase in
the MEP amplitude reﬂects the presence of fewer and large motor
units in ALS. This notion may be supported by previous studies
using the triple stimulation technique that revealed a maximal
TMS stimulus was capable of activating nearly all motor neurons
supplying the target muscle (Magistris et al., 1998). In contrast to
the triple stimulation technique ﬁndings, single pulse TMS studies
have established that the MEP amplitudes were normal in condi-
tions with a comparable degree of lower motor neuron loss, such
as Kennedy’s disease (X-linked spinobulbar muscular atrophy) and
hereditary motor neuronopathy with pyramidal signs (Vucic and
Kiernan, 2008; Vucic et al., 2010). Furthermore, longitudinal peri-
stimulus time histogram studies in patients with ALS did not report
an increase in the primary peak amplitude, which might be ex-
pected with the presence of large motor units (Weber et al.,
2000). Although considered less likely, the possibility that larger
and fewer motor units are contributing to the increased MEP
amplitude in the present study cannot be discounted.
Diagnostic utility of threshold
tracking TMS
The diagnosis of acquired neuromyotonia relies on the presence of
clinical symptoms combined with neurophysiological ﬁndings of
doublet, triplet or multiplet (‘myokymic’) motor unit discharges
and fasciculations (Hart et al., 2002). Although the clinical features
of acquired neuromyotonia and ALS may be different, with pa-
tients with acquired neuromyotonia exhibiting a faster fascicula-
tion frequency (Hart et al., 2002), in certain clinical scenarios
acquired neuromyotonia may be misdiagnosed as ALS. This may
be the case when cramps and fasciculations are accompanied by
clinical weakness, as may occur when acquired neuromyotonia is
associated with a motor polyneuropathy (Newsom-Davis, 1997;
Hart et al., 2002). Moreover, anti-VGKC antibodies 4100pM
were reported in up to 5% of individuals 450 years (Vincent
et al., 2004), and recently in 30% of patients with ALS (Nwosu
et al., 2010), although the latter study did not state the cut-off for
normal values recommended by the laboratory involved.
In addition, fasciculations may be the sole presenting feature of
ALS (Gubbay et al., 1985), developing prior to ﬁbrillation poten-
tials, positive sharp waves and chronic neurogenic changes
(de Carvalho et al., 1999; de Carvalho and Swash, 2004). Such
presentations may result in misdiagnosis and ultimately a delay in
the institution of appropriate management. The contrasting ﬁnd-
ing of cortical excitability suggests that the threshold tracking TMS
technique may be of diagnostic utility in differentiating acquired
neuromyotonia from ALS, particularly in the early disease stages.
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